This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EVT 103

Evotec AG

Drug Names(s): EVT103

Description: EVT 103 is a small molecule NR2B-selective NMDA receptor antagonist and is the follow-on compound to EVT 101.

NMDA receptors are involved in the pathology of depression. NR2B-selective antagonists bind preferentially to the activated form of the NMDA receptor containing the NR2B subunit and allosterically modulate, in an activity-dependent manner, channel activity by inhibiting channel opening probability. They show advantages over non-selective NMDA antagonists due to greater separation of efficacy from side effects.

Deal Structure: In March 2004, Evotec announced that it has acquired from Roche an exclusive worldwide license to develop and market an extensive patent portfolio covering NMDA receptor NR2B subtype selective antagonists for the treatment of a variety of CNS disorders. Roche has retained rights to reacquire the compounds in the future. Financial details of the collaboration were not disclosed.

In December 2012, Evotec announced that it has entered into a license agreement with Janssen Pharmaceuticals. Under the terms of this agreement Janssen has been granted an exclusive, worldwide license to a series of small molecule drug candidates. Janssen has the exclusive right to further develop the compounds and market the resulting products.

Partners: Roche Holding AG Johnson & Johnson

EVT 103 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug